NUMonk

[Parker Institute for Cancer Immunotherapy @parkerici]

Yesterday, PICI convened a congressional briefing on Capitol Hill exploring the transformative potential of cancer vaccines.

We were honored to be joined by cancer vaccine recipients and advocates from across the country, Congresswoman @DWStweets, @TheVinodLab from @MSKCancerCenter, and other leaders committed to advancing research and innovation. Several cancer vaccine recipients and PICI leaders also met with Senator Todd Young to discuss the promise of cancer vaccines and help raise awareness of their potential impact on patients.

Hearing these powerful stories and conversations serves as a reminder of what is possible when scientific innovation, patient advocacy, and public investment come together to drive progress against cancer. PICI is proud to help advance conversations and collaborations needed to bring these promising therapies to more patients.

[Amanda Hollensbe (Braelyn’s Mom) @HollensbeAmanda]

💜 DCVax Long-Term Survivor Series — Part 7 💜

Tonight I want to share the story of Kat Charles from the UK.

After undergoing surgery, radiation, chemotherapy, and even participating in a clinical trial, Kat was told there was nothing more doctors could do. She and her husband Jason were told she had approximately three months to live.

Instead of accepting that prognosis, they kept searching for options.

The family ultimately raised funds to access DCVax.

Years later, Kat told the BBC that scans showed no visible tumor. Her husband Jason said:

“DCVax has done what everyone said was impossible.”

Even more remarkably, Kat later shared that she was still receiving ongoing DCVax injections every six months and was alive 11 years after her glioblastoma diagnosis.

When I was told that long-term glioblastoma survivors don’t exist, stories like Kat’s are exactly why I refused to stop looking.

Every survivor has a story.

Every family deserves hope.

And every patient deserves the chance to fight for their future.

💜 #DCVaxForBraelyn #BrainCancerAwarenessMonth

https://t.co/79rHKEgNR8

[rj @sharpie510]

One such example is Brad Silver, who received a therapeutic cancer vaccine for stage IV #glioblastoma in 2003. At the time, he was given just two months to live. Twenty-two years later, Silver is thriving.
💪
FreezeYourTumor
GetDCVax

#gbm $nwbo #dcvax

https://t.co/Gkr8CBOKzr

[NWBOstacks @EatYerShorts]

NWBO longs know the game:

Good news --> shorts + aligned media attack.

Dr. Liau keeps doing the work. Feuerstein keeps tweeting.

Science will win eventually.

[NWBOstacks @EatYerShorts]

Feuersteins "malevolent" whisper wasn't journalism.

It was reckless speculation that contributed to real harm:

Retail investors wrecked. Patient hope attacked. And a promising therapy buried under the noise.

Patients with GBM don't have time for this shit. 👇

[NWBOstacks @EatYerShorts]

Dr. Liau DID subsequently present the full data at Society for Neuro-Oncology in November 2022, showing meaningful survival extensions in GBM.

She stood by the science.

There was no "planned" withdrawal drama. Just a doctor who got sick. And a "journalist" being a dick. 👇

[NWBOstacks @EatYerShorts]

This wasn't neutral reporting.

This was narrative warfare during a critical data drop.

Combined with his hit piece calling the results "a failure," ignoring the strong OS data.

He amplified the FUD storm. Shorts piled on. Stock wiped out $1.6B+ in market cap. 👇

[NWBOstacks @EatYerShorts]

Enter Feuerstein's tweets on May 9-10:

"For those interested in $NWBO, Dr. Linda Liau is no longer speaking..."

"There is also a weird (perhaps malevolent) story... Dr. Linda Liau's last-minute withdrawal may not have been an unlucky occurrence due to illness. It may have been planned."

Pure speculation. Zero evidence. Just poison. 👇

[NWBOstacks @EatYerShorts]

Last minute, Dr. Liau had to withdraw. She'd come down with COVID, like countless others in 2022.

Dr. Paul Mulholland stepped in and presented via Zoom.

Company and attendees confirmed it was illness. No mystery. 👇

[NWBOstacks @EatYerShorts]

Background:

Dr. Linda Liau (UCLA neurosurgeon, principal investigator) was scheduled to present the long-awaited DCVax-L glioblastoma data at the NY Academy of Sciences conference.

Huge moment for patients fighting one of the deadliest cancers. 👇

[NWBOstacks @EatYerShorts]

Adam Feuerstein spent years trashing $NWBO.

But on May 10, 2022, the day positive DCVax-L Phase 3 survival data dropped, he went full conspiracy clown.

This tweet below helped fuel the chaos that crushed the stock 82% in one day.

Let's recap his garbage 👇

[Thomas Owen McCaffrey @ThomasOwenMcCa1]

Kenneth C. Griffin IS LAUGHING AT ALL THE PEOPLE DIAGNOSED WITH GLIOBLASTOMA MULTIFORME. (The most aggressive form of brain 🧠 CANCER.
People die everyday but this is different, he knows that there is a CURE FOR THIS BARBARIC DISEASE. But his hedge fund suppresses that CURE. Yes, @citsecurities the hedge fund he MANAGES is killing people every single DAY. & for what? GREED, how much money 💰 does he have to make before someone stops him. Let’s see how this plays out shall we. We already know the @SECGov is a JOKE.

@HollensbeAmanda @AZhalala @kshaughnessy2 @LisainNJUSA @NYMag @NorthwestBio @stephmase22 @ElvirPons @mcuban @TheLastWord @LastWeekTonight @hoffmann6383

[Doc T @DoctorStock06]

$NWBO October 6th will make 6 yrs since the P3 trial was data locked (2020). The average biotech takes 6-10 yrs from a P1 trial, through FDA approval. For us, it’s been nearly 6 yrs just since the P3 trial ended, and we still don’t have a single approval. Absolutely mind-boggling

[NWBOstacks @EatYerShorts]

"Trial failed...data's garbage...she's hiding failure...delaying the truth." BULLSHIT

Phase 3 data (published in JAMA Oncology) showed clear survival benefit: median OS 19.3 vs 16.5 months nGBM, 13.2 vs 7.8 months rGBM, with stronger long tails. External validation keeps coming, manufacturing scale-up is rolling, regulators engaged.

The "delay" is fighting the FUD war + building real infrastructure. Data will drop when it's locked and loaded, not on shorts' schedule.

- - - - -

These assholes keep recycling these attacks, because the science + Linda's will to win keep surviving their bullshit. 💩

[NWBOstacks @EatYerShorts]

"Overpaid CEO sucking the company dry with salary/options while it bleeds cash." BULLSHIT

Base comp around $925k (below average for similar biotechs). She's taken massive personal risk as a huge shareholder with skin in the game. Most CEOs bail or pivot to easier gigs; she's been grinding this for 15+ years.

Dilution sucks but it's literal survival mode against relentless shorting. 👇

[NWBOstacks @EatYerShorts]

"Predatory lender, she loans money at crazy rates then gets repaid fat!" BULLSHIT

When the company was starved for cash (thanks to constant short attacks and no bank financing), she stepped up with bridge loans others wouldn't touch. Repaid with interest like any lender in high-risk situations.

This kept NWBO alive trying to skirt far worse dilution at rock-bottom prices. Shareholders are still here because she refused to let it die. 👇

[NWBOstacks @EatYerShorts]

"Former Enron exec—guilty by association, total crook!" BULLSHIT.

LP worked in project finance at Enron International (overseas infrastructure deals) and left in 1997, years before the fraud schemes started in other parts of the company. Zero involvement, zero charges, never mentioned in any investigations.

Classic lazyass FUD: smear her with a company she left clean, while she's ground out 15+ years at NWBO through every short attack imaginable. 👇

[NWBOstacks @EatYerShorts]

"She's running a Ponzi, enriching herself with related-party scams via Cognate/Toucan." BULLSHIT.

All transactions fully disclosed in SEC filings for years, with Conflicts Committee review and pre-approvals. She poured her own money in via bridge loans when others wouldn't. No fraud findings, no convictions, just disclosed deals that kept the company alive.

FUD trolls hate that she controls her own destiny instead of kissing Big Pharma ass. 👇

[NWBOstacks @EatYerShorts]

Linda Powers. This is a tough, TOUGH woman leading NWBO.

It's not enough they try to short her company into the dirt. FUDpackers trash her personal reputation as well, while she tries to bring hope to cancer patients. Nice.

I'll call BS on 5 of their biggest smears. 👇

[alphavestcapital.com @alphavestcap]

$nwbo @alphavestcap

https://t.co/RyCWCBm8Kl

The Northwest Biotherapeutics Empire Forecast 2030: Why Northwest Biotherapeutics Is the Most Underestimated Cancer Immunotherapy Company in the World
📷
Key Takeaways
Northwest Biotherapeutics (NWBO) is building a vertically integrated personalized cancer vaccine platform centered around dendritic cell immunotherapy.
The company’s lead asset, DCVax-L, targets glioblastoma (GBM), one of the deadliest cancers with few effective treatments.
NWBio is evolving from a single-product biotech into a manufacturing + platform immunotherapy ecosystem through Flaskworks automation and Advent BioServices integration.
The market may still be pricing NWBO like a speculative OTC biotech rather than a future oncology infrastructure platform.
If regulatory approvals materialize and manufacturing scales successfully, NWBO could become one of the largest independent cellular immunotherapy franchises by 2030.
Major upside drivers include:Personalized oncology
Cancer vaccines
AI-assisted biologics manufacturing
Cell therapy automation
Immunotherapy expansion into solid tumors

Key risks remain:Regulatory delays
Funding dilution
Commercial execution
Manufacturing complexity
Competition from larger oncology players

The Empire No One Fully Prices
Most investors still view Northwest Biotherapeutics as a small speculative biotech company trading on the OTC market.
That may be the single biggest misunderstanding surrounding the company.
What NWBio appears to be building is not merely a single cancer drug — but a fully integrated personalized immunotherapy ecosystem.
The company’s long-term vision increasingly includes:
Proprietary dendritic cell vaccine IP
Automated manufacturing systems
Clinical oncology infrastructure
Personalized vaccine logistics
GMP manufacturing
Cryostorage capabilities
Scalable production automation
Future multi-cancer platform expansion
Its ecosystem now spans:
DCVax-L
DCVax-Direct
Flaskworks EDEN automation
Advent BioServices manufacturing
Potential future solid tumor applications
UK/EU regulatory positioning
The market cap remains extremely small relative to the potential oncology markets involved. Reported market capitalization estimates have generally ranged in the hundreds of millions rather than multi-billions.
That asymmetry is why NWBO remains one of the most controversial and potentially misunderstood healthcare stories heading into 2030.
Business / Asset Breakdown
SegmentDescriptionStrategic ImportanceDCVax-LPersonalized dendritic cell vaccine for glioblastomaCore commercial opportunityDCVax-DirectImmunotherapy for inoperable tumorsLong-term expansion platformFlaskworks EDENAutomated vaccine manufacturing platformPotential margin and scalability breakthroughAdvent BioServicesGMP manufacturing subsidiaryVertical integrationUK MHRA PositioningRegulatory pathway in UKPotential first commercialization regionTumor Vaccine PlatformPersonalized solid tumor immunotherapyMulti-cancer optionalityCryostorage InfrastructureCell therapy logisticsOperational moatIP PortfolioManufacturing + immunotherapy patentsLong-term defensibility
Major Investment 1: DCVax-L
DCVax-L remains the centerpiece of the NWBO investment thesis.
The therapy is designed to use a patient’s own dendritic cells combined with tumor lysate to create a personalized anti-cancer immune response.
The company completed a 331-patient Phase III trial in glioblastoma. Results were published in JAMA Oncology and showed survival improvements versus external controls.
Glioblastoma is one of the most lethal forms of cancer, with historically poor survival outcomes.
If approved commercially, DCVax-L could become one of the first broadly validated personalized dendritic cell vaccine therapies for solid tumors.
The long-term significance may extend beyond GBM itself.
The real strategic value could be proving:
Personalized vaccine feasibility
Commercial manufacturability
Reimbursement viability
Repeatable cell therapy infrastructure
That could unlock applications across multiple tumor types by 2030